Are SSRIs Safe Long Term? What the Research Really Says

Selective serotonin reuptake inhibitors (SSRIs) are some of the most widely prescribed medications in the world. Millions of people take them not just for a few months, but for years. It’s no surprise patients and families ask the same question again and again: are SSRIs actually safe to take long term?

The answer is nuanced. The science says SSRIs can be both highly effective and generally safe when used over extended periods, but there are real risks that deserve attention. Here’s a breakdown of what we know from large meta-analyses and systematic reviews.

The Benefits: Why Doctors Prescribe SSRIs for the Long Haul

A major network meta-analysis published in Molecular Psychiatry in 2022 looked at antidepressants in the maintenance phase of major depressive disorder. The takeaway: SSRIs are effective at preventing relapse and are reasonably well tolerated over time. For many people, staying on medication long term can mean fewer relapses, fewer hospitalizations, and more stability in daily life.

So from an efficacy standpoint, the research supports their use beyond the short term — especially in people with moderate to severe depression who relapse when medication is stopped.

The Risks: What Long-Term Studies Show

The flip side is that SSRIs are not risk-free, and long-term data show some patterns clinicians and patients need to keep in mind.

Sexual Side Effects
Sexual dysfunction is one of the most common long-term issues. Meta-analyses consistently show higher rates of problems like reduced libido, delayed orgasm, or erectile difficulties. Rarely, symptoms may persist even after the drug is discontinued, a condition sometimes called post-SSRI sexual dysfunction (PSSD).

Weight, Energy, and Emotional Changes
Some people develop weight gain, daytime sleepiness, or a sense of emotional blunting over the years. These aren’t life-threatening but can have a major impact on quality of life.

Bone Health
Systematic reviews have found that SSRIs are associated with lower bone mineral density and higher fracture risk, particularly in older adults. This doesn’t mean everyone will develop bone issues, but it’s important to monitor, especially if other risk factors are present.

Cardiovascular Health
A large meta-analysis found long-term SSRI users had a modestly increased risk of all-cause mortality (around 33%) and cardiovascular complications (about 14%). These numbers sound big, but context matters because depression itself increases cardiac risk. So it’s difficult to know how much of this is the medication versus the underlying illness.

Discontinuation Syndrome
One of the clearest risks is what happens when SSRIs are stopped suddenly. Up to half of people experience withdrawal-like symptoms: dizziness, nausea, flu-like feelings, and “brain zaps.” Symptoms are usually reversible, but can be very distressing if the drug is stopped too quickly.

Other Concerns
There’s mixed evidence linking SSRIs with cataracts, cognitive changes, or gastrointestinal bleeding. These risks are more relevant in older adults or those with medical comorbidities.

Special Populations

• Young Adults (under 25): Research shows a small but real increase in suicidal thinking during the first months of treatment. Monitoring during initiation is critical.

• Elderly Patients: More vulnerable to bone loss, falls, and possibly cognitive frailty with long-term SSRI exposure.

• Pregnant and Breastfeeding Patients: Some SSRIs are safer than others; paroxetine, for example, is linked to congenital risk. Decisions in pregnancy must balance maternal mental health with potential fetal impact.

Putting It All Together

So, are SSRIs safe long term? The best answer is: generally yes, but with caveats.

• They are proven to reduce relapse risk and maintain stability in depression and anxiety disorders.

• Side effects are real but often manageable with monitoring and adjustments.

• Long-term use requires intentional check-ins, bone health, weight, cardiovascular risk, and sexual functioning should all be part of routine follow-up.

• No one should stop SSRIs abruptly; tapering slowly with a clinician’s guidance makes discontinuation far safer.

• SSRIs should not be viewed as a “set it and forget it” pill. They work best as part of a broader treatment plan that includes therapy, lifestyle interventions, and ongoing evaluation.

My Perspective as a Psychiatric Provider

In my practice, I’ve seen SSRIs give people their lives back when depression or anxiety felt unmanageable. But I’ve also seen how frustrating long-term side effects can be if they’re not addressed. My approach is to use SSRIs thoughtfully: with clear goals, active monitoring, and a plan for when and how to eventually taper if possible.

SSRIs can absolutely be safe for long-term use, but only when paired with the right support, regular reassessment, and honest conversations about risks and benefits.

References

1. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of antidepressants for major depressive disorder in adults: a network meta-analysis. Lancet. 2018;391(10128):1357-1366. [PubMed PMID: 29477251]

2. Furukawa TA, Cipriani A, Cowen PJ, et al. Antidepressants in the maintenance treatment of major depression: a systematic review and network meta-analysis. Molecular Psychiatry. 2022. Nature link

3. Jakobsen JC, Katakam KK, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry. 2017;17:58. PMC5357202

4. Serretti A, Chiesa A. Sexual side effects of antidepressant treatment: an overview. J Clin Pharmacol. 2009;29(4):259-273. [PubMed PMID: 19341008]

5. Bala A, Nguyen HM, Hellstrom WJ. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018;6(1):29-34. [PubMed PMID: 28566265]

6. Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int. 2012;23(1):365-375. [PubMed PMID: 21369726]

7. Maslej MM, Bolker BM, Russell MJ, et al. The mortality and cardiovascular risk of antidepressants: a meta-analysis of observational studies. Psychother Psychosom. 2017;86(5):268-282. [PubMed PMID: 28848283]

8. Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72-81. [PubMed PMID: 25721902]

9. Etminan M, Sodhi M, Samii A, Procyshyn RM, Guo M, Carleton BC. Selective serotonin reuptake inhibitors and risk of cataracts: a nested case–control study. Ophthalmology. 2010;117(6):1251-1255. [PubMed PMID: 20227729]

10. Coupland C, Hill T, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551. [PubMed PMID: 21810886]

11. National Center for Biotechnology Information. Antidepressant medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NCBI Bookshelf